Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
Volume 12, Issue 1 , Pages 106-111 , 2009

Evaluation, Risk Stratification, and Management of Pulmonary Hypertension in Patients With Congenital Heart Disease

  • Jeffrey A. Feinstein

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jeffrey A. Feinstein, MD, Associate Professor, Pediatrics, Division of Pediatric Cardiology, Lucile Packard Children's Hospital/Stanford University Medical Center, 750 Welch Road, Suite 305, Palo Alto, CA 94025

References 

  1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S
  2. Beghetti M, Barst R, Naeije R, Rubin LJ. Pulmonary Arterial Hypertension Related to Congenital Heart Disease. Munich, Germany: Elsevier GmbH; 2006;
  3. Landzberg MJ. Congenital heart disease associated pulmonary arterial hypertension. Clin Chest Med. 2007;28:243–253
  4. Viswanathan S, Kumar RK. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv. 2008;71:665–670
  5. St. John Sutton MG, Tajik AJ, McGoon DC. Atrial septal defect in patients ages 60 years or older: Operative results and long-term postoperative follow-up. Circulation. 1981;64:402–409
  6. Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease-Long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987;76:1037–1042
  7. Weidman WH, Gilbert Blount S, Dushane JW, et al. Clinical course in ventricular septal defect. Circulation. 1977;56(suppl 1):56–69
  8. Moller JH, Patton C, Varco RL, et al. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol. 1991;68:1491–1497
  9. Kannan BR, Sivasankaran S, Tharakan JA, et al. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J. 2003;55:161–166
  10. Yasui H, Takeda Y, Yamauchi S, et al. The deleterious effects of surgically induced complete right bundle branch block on long-term follow-up results of closure of ventricular septal defect. J Thorac Cardiovasc Surg. 1977;74:210–217
  11. Kawashima Y, Mori M. The early and late effects of surgical closure of ventricular septal defects on pulmonary vascular dynamics. Jpn Circ J. 1976;40:637–643
  12. Ikawa S, Shimazaki Y, Nakano S, et al. Pulmonary vascular resistance during exercise late after repair of large ventricular septal defects (Relation to age at the time of repair). J Thorac Cardiovasc Surg. 1995;109:1218–1224
  13. Lock JE, Einzig S, Bass JL, et al. The pulmonary vascular response to oxygen and its influence on operative results in children with ventricular septal defect. Pediatr Cardiol. 1982;3:41–46
  14. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): The INOP test study group. Circulation. 2002;106(suppl 12):I76–I81
  15. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension (The International PPH Consortium). Nat Genet. 2000;26:81–84
  16. Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2004;24:371–374
  17. Elliott CG, Glissmeyer EW, Havlena GT, et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation. 2006;113:2509–2515
  18. Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med. 2008;177:1377–1383
  19. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436
  20. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs. 2008;68:1049–1066
  21. Beghetti M. Current treatment options in children with pulmonary arterial hypertension and experiences with oral Bosentan. Eur J Clin Invest. 2006;36(suppl 3):16–24
  22. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005;111:3274–3280
  23. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study (BREATHE-5). Circulation. 2006;114:48–54
  24. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension (SUPER). N Engl J Med. 2005;353:2148–2157
  25. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115:1039–1050
  26. Schwerzmann M, Zafar M, McLaughlin PR, et al. Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy. Int J Cardiol. 2006;110:104–107
  27. Frost AE, Quiñones MA, Zoghbi WA, et al. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant. 2005;24:501–503
  28. Frigiola A, Tsang V, Bull C, et al. Biventricular response after pulmonary valve replacement for right ventricular outflow tract dysfunction: is age a predictor of outcome?. Circulation. 2008;118(suppl 14):S182–S190
  29. Dubin AM, Feinstein JA, Reddy VM, et al. Electrical resynchronization: A novel therapy for the failing right ventricle. Circulation. 2003;107:2287–2289

PII: S1092-9126(09)00011-8

doi: 10.1053/j.pcsu.2009.01.010

Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
Volume 12, Issue 1 , Pages 106-111 , 2009

Article Tools